Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.8652W HIGH $5.93
Volume
1.18 M
Value Traded
1.33 M
Short % Float
6.2%
-19%Week
-36.82%1 Month
-54.22%3 Month
-46.76%6 Month
-86.96%5 Year
-79.33%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
57.17 M
EPS (TTM)
-0.38
P/E Ratio
-
Ent. Value
12.08 M
Total Shares
60.35 M
Float Shares
58.10 M
Insiders
3.70%
Institutions
60.74%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
ALDX Catalyst Timeline
Dated clinical, regulatory and corporate events for Aldeyra Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Aldeyra Therapeutics, Inc.
469Total events
3Upcoming
149Tier-1 (high impact)
2014 to 2029Coverage
Upcoming catalysts 2
Event history 50
●R&D DayReproxalapFiledPresentation
Aldeyra to host regulatory update webcast on reproxalap for dry eye disease
dry eye diseasesource ↗
◆Type A MeetingReproxalapFiledFDA Meeting
Aldeyra intends to request Type A meeting with FDA to discuss NDA approval path
dry eye diseasesource ↗
▼Complete Response LetterReproxalapFiledFDA Decision
FDA issued Complete Response Letter for reproxalap NDA for dry eye disease
dry eye diseasesource ↗
◆PDUFA DateReproxalapFiledRegulatory Filing
PDUFA target action date extended to March 16, 2026
dry eye diseasesource ↗
▼Complete Response LetterReproxalapFiledFDA Decision
FDA Complete Response Letter denied NDA approval for reproxalap in dry eye disease
dry eye diseasesource ↗
◆Oral PresentationPresentation
Aldeyra to participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference fireside chat
◆PDUFA DateReproxalapFiledRegulatory Filing
PDUFA target action date for NDA resubmission (6 months from submission)
dry eye diseasesource ↗
◆PDUFA DateReproxalapFiledRegulatory Filing
PDUFA target action date set for reproxalap NDA
dry eye diseasesource ↗
●Major Amendment SubmittedReproxalapFiledRegulatory Filing
Clinical Study Report for field trial submitted to NDA as major amendment
dry eye diseasesource ↗
◆FDA Feedback ReceivedReproxalapFiledFDA Meeting
FDA shared draft prospective label; Aldeyra submitted response
dry eye diseasesource ↗
▲Topline ReadoutADX-629Clinical Data
Positive topline results from Phase 2 trial of ADX-629 in alcohol-associated hepatitis
alcohol-associated hepatitissource ↗
◆Timing GuidanceReproxalapFiledPresentation
FDA acceptance of NDA resubmission for review expected within 30 days
dry eye diseasesource ↗
▲FDA Filing AcceptedReproxalapFiledRegulatory Filing
NDA accepted for review as complete class 2 response
dry eye diseasesource ↗
◆Trial InitiationADX-2191FiledTrial
Clinical trial expected to begin in second half of 2025
primary vitreoretinal lymphomasource ↗
▲SPA AgreementADX-2191FiledFDA Meeting
FDA Special Protocol Assessment Agreement for ADX-2191 for PVRL
primary vitreoretinal lymphomasource ↗
●NDA SubmissionReproxalapFiledRegulatory Filing
Resubmission of NDA for reproxalap for dry eye disease
dry eye diseasesource ↗
◆Timing GuidanceReproxalapFiledPresentation
Potential NDA resubmission anticipated mid-2025
Dry Eye Diseasesource ↗
▲Topline ReadoutReproxalapFiledClinical Data
Phase 3 dry eye chamber trial achieved primary endpoint of ocular discomfort with statistical significance (P=0.002)
dry eye diseasesource ↗
●Type A MeetingReproxalapFiledFDA Meeting
Aldeyra requested Type A meeting with FDA to discuss NDA resubmission
dry eye diseasesource ↗
▼Topline ReadoutReproxalapFiledClinical Data
Top-line results for field trial announced; did not meet primary endpoint
dry eye diseasesource ↗
◆Type A MeetingReproxalapFiledFDA Meeting
Type A meeting with FDA to discuss CRL and ongoing trials
Dry Eye Diseasesource ↗
▲Primary Endpoint MetReproxalapFiledClinical Data
Phase 3 dry eye chamber trial achieved primary endpoint (P=0.002)
dry eye diseasesource ↗
▼Complete Response LetterReproxalapFiledFDA Decision
FDA issued Complete Response Letter for reproxalap NDA resubmission
dry eye diseasesource ↗
◆PDUFA DateReproxalapFiledRegulatory Filing
PDUFA target action date for reproxalap NDA resubmission (6 months from submission)
dry eye diseasesource ↗
▲Topline ReadoutReproxalapFiledClinical Data
Positive Phase 3 INVIGORATE 2 top-line results announced
Allergic Conjunctivitissource ↗
◆PDUFA DateReproxalapFiledRegulatory Filing
PDUFA date set for reproxalap NDA for dry eye disease
dry eye diseasesource ↗
▼Complete Response LetterReproxalapFiledFDA Decision
Received Complete Response Letter from FDA
dry eye diseasesource ↗
●Timing GuidanceReproxalapFiledPresentation
NDA resubmission anticipated in mid-2025
dry eye diseasesource ↗
◆Topline ReadoutReproxalapFiledClinical Data
Top-line results from dry eye disease chamber trial expected
Dry Eye Diseasesource ↗
●Timing GuidanceReproxalapFiledPresentation
Anticipated six-month FDA review period for NDA resubmission
dry eye diseasesource ↗
●IND SubmissionADX-631IND
IND application expected to be submitted in 2025
dry age-related macular degeneration/geographic atrophysource ↗
●IND SubmissionADX-743IND
IND application expected to be submitted in 2025
obesity/hypertryglyceridemiasource ↗
◆Topline ReadoutADX-629Clinical Data
Phase 2 pediatric cohort top-line results expected in 2025
Sjögren-Larsson Syndromesource ↗
●Trial InitiationADX-2191FiledTrial
Phase 2/3 clinical trial initiation expected in 2025
retinitis pigmentosasource ↗
▲Topline ReadoutReproxalapFiledClinical Data
Positive Phase 3 INVIGORATE 2 trial top-line results announced
allergic conjunctivitissource ↗
▲FDA Filing AcceptedReproxalapFiledRegulatory Filing
FDA accepted for review resubmitted NDA for reproxalap for dry eye disease
dry eye diseasesource ↗
▲Partnership / LicenseReproxalapFiledCorporate
Expanded option agreement with AbbVie for reproxalap
dry eye diseasesource ↗
◆Timing GuidanceReproxalapFiledPresentation
FDA acceptance of NDA resubmission for review expected within 30 days
dry eye diseasesource ↗
●NDA SubmissionReproxalapFiledRegulatory Filing
Resubmission of NDA for reproxalap for dry eye disease
dry eye diseasesource ↗
▲Primary Endpoint MetReproxalapFiledClinical Data
Phase 3 dry eye chamber trial achieved success for primary endpoint of ocular discomfort
dry eye diseasesource ↗
Past FDA Catalysts and PDUFA Decisions
How ALDX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-03-17 | Reproxalap (RASP modulator) | PDUFA Date CRL | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C45 / 100
Pipeline Score
$205M
Pipeline Value
Fair Value
Valuation Signal
4
Drugs Scored
2.9x
rNPV / MCap
Top 27%
Micro Cap(rank 178 of 658)
Percentile Rank
Aldeyra Therapeutics, Inc. carries a moderate pipeline score (45/100), with $820M risk-adjusted pipeline value, led by ADX-629 in Plaque Psoriasis (Phase 2), across $159B in total addressable markets.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ADX-629 Small moleculeCompletedNCT04847544 | Covid19 | Phase 2 | COMPLETED | 11 | Oct 15, 2021 |
Clinical Trial Results
Readouts, endpoints and source filings for every ALDX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ADX-629 | alcohol-associated hepatitis | Phase 2 | 2025-10-28 | MELD score: P=0.001; triglyceride levels: P<0.0001; C Reactive Protein: P<0.0001Read More | candidates; Aldeyra's expectations regarding competition; Aldeyra's anticipated growth strategies; Aldeyra's ability to attract or retain key personnel; Aldeyra's commercialization, marketing and manufacturing capabilitiRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Brady Todd CDirector, Officer (President and CEO) | Buy | 250,000 1,721,298 held | $1.67 | 06/03/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ALDX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Palo Alto Investors LP | 0 % | 331.00 K | 155.71 K |
ALDX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-30 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ALDX ranks across every disease it competes in
Competitive Position is a premium feature
See how ALDX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialALDX News
ALDX▲ +13.8%on this news
Aldeyra Therapeutics Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap to Treat Dry Eye Disease
Aldeyra Therapeutics has announced its intention to submit a Formal Dispute Resolution Request (FDRR) to the FDA regarding reproxalap, an investigational treatment for dry eye disease. This step reflects the company's commitment to addressing regulatory challenges as it seeks approval for the drug. The FDRR will be reviewed by the FDA's Office of New Drug.
Read more →ALDX▲ +13.8%on this newsshared move
Aldeyra Therapeutics to Host Regulatory Update Webcast
Aldeyra Therapeutics will host a regulatory update webcast on September 29, 2026, focusing on reproxalap, its investigational drug for dry eye disease. This event aims to provide insights into the drug's development and regulatory status. The webcast will include a live audio presentation and slides for attendees.
Read more →ALDXAldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of Directors
Aldeyra Therapeutics has appointed Darlene Deptula-Hicks to its Board of Directors. This move is part of the company's ongoing efforts to strengthen its leadership team. Details regarding her background and the implications of this appointment have not been disclosed in the article.
Read more →ALDXAldeyra Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
Aldeyra Therapeutics is set to participate in the 2026 Jefferies Global Healthcare Conference. This event will provide a platform for the company to discuss its developments and future plans. Details regarding the specific topics to be addressed during the conference have not been disclosed.
Read more →ALDX▼ -70.7%on this news
Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease
Aldeyra Therapeutics has received a Complete Response Letter from the FDA regarding its New Drug Application for reproxalap, intended for treating dry eye disease. The FDA cited insufficient evidence of efficacy from clinical trials and expressed concerns about the reliability of positive findings. Aldeyra plans to request a Type A meeting to discuss the next steps for potential approval.
Read more →ALDXAldeyra Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Aldeyra Therapeutics announced that its CEO, Dr. Todd C. Brady, will participate in a virtual fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference. The event is scheduled for February 25, 2026, at 10:40 a.m. ET. The discussion will be available for live viewing and archived for 90 days on Aldeyra's website.
Read more →ALDX▲ +33.1%on this news
Aldeyra Therapeutics Announces PDUFA Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye Disease
Aldeyra Therapeutics announced that the FDA has extended the PDUFA target action date for its New Drug Application (NDA) for reproxalap, aimed at treating dry eye disease, to March 16, 2026. This extension follows the acceptance of the NDA, which was completed on July 16, 2025. However, the drug's field trial did not meet its primary endpoint, raising questions about future commercial viability. Aldeyra submitted additional data to address FDA requests, and a response to the draft label has been provided, with further communications expected by February 16, 2026.
Read more →ALDX▼ -5.3%on this news
Aldeyra Therapeutics Announces Expansion of RASP Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development Webcast
Aldeyra Therapeutics announced the expansion of its RASP platform to address central nervous system diseases, supported by promising preclinical results in models of Parkinson's disease and ALS. The company also provided updates on reproxalap's manufacturing, confirming successful FDA inspections. The CEO expressed optimism about the potential of ADX-248 and other RASP modulators.
Read more →ALDX▼ -5.3%on this news
Disclaimers and Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act o
Aldeyra Therapeutics presented an overview of its research and development plans, highlighting its pipeline of potential therapies targeting immune-mediated diseases. The company identified multiple forward-looking statements, emphasizing the uncertainties regarding the outcomes of clinical trials and regulatory approvals. They reported a cash position of $75.3 million, expected to sustain operations through the second half of 2027. Aldeyra also acknowledged potential risks that could affect its development timelines and overall performance.
Read more →ALDXAldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
Aldeyra Therapeutics announced its participation in the 2025 Jefferies Global Healthcare Conference in London. CEO Todd C. Brady will engage in a fireside chat on November 20, 2025, discussing the company's innovative therapies for immune-mediated diseases. The event will be available for live streaming and archived for later viewing.
Read more →ALDXAldeyra Therapeutics to Host Research & Development Update Webcast Event Scheduled for Thursday, November 13 at 8:00 a.m. ET
Aldeyra Therapeutics will host a Research & Development Update webcast on November 13, 2025, at 8:00 a.m. ET. The event will review the company's pipeline programs and include presentations from its senior leadership team. A live audio webcast will be available on their website for 90 days post-event.
Read more →ALDXAldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules -Relative to Baseline, Signal-Finding Molecule ADX 629 Demonstrated Statistically Significant Improvement in Liver Function in Patients with Alcohol-Associated Hepatitis
Aldeyra Therapeutics announced positive results from its Phase 2 clinical trial for ADX-629, a signal-finding RASP modulator, which demonstrated significant improvements in liver function in patients with alcohol-associated hepatitis. The company has shifted its pipeline focus to next-generation RASP modulators ADX-248 and ADX-246 for various immune-mediated diseases. Aldeyra also reported that its cash runway is extended into the second half of 2027, ensuring operational stability amidst clinical developments, although ADX-629's clinical development has been discontinued pending further investigations. The outcomes of regulatory submissions and market acceptance remain critical factors for Aldeyra's future growth.
Read more →ALDXAldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease
Aldeyra Therapeutics announced that the FDA has accepted the resubmission of its New Drug Application for reproxalap, aimed at treating dry eye disease. The FDA has set a target action date of December 16, 2025. Reproxalap is notable for achieving the primary endpoint in clinical trials. However, the FDA mandated further clinical trials to validate efficacy.
Read more →ALDX▲ +10.3%on this news
Aldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma
Aldeyra Therapeutics announced that it has received a Special Protocol Assessment Agreement Letter from the FDA for its investigational drug ADX-2191, aimed at treating primary vitreoretinal lymphoma. The drug, a new formulation of methotrexate designed for intraocular injection, currently lacks FDA-approved therapies. Following a prior Complete Response Letter, it is now set to undergo a clinical trial comparing treatment efficacy between a single injection and multiple injections. The trial is expected to commence in the latter half of 2025 and conclude by 2026.
Read more →ALDXAldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease
Aldeyra Therapeutics has resubmitted its New Drug Application for reproxalap to the FDA for the treatment of dry eye disease. The submission includes data from a recently completed clinical trial that met its primary endpoint, addressing previous concerns from the FDA. The company remains hopeful as there were no significant safety issues reported in the trials. This resubmission marks a vital step for Aldeyra in progressing reproxalap toward potential approval.
Read more →ALDX▼ -22.2%on this news
Topline Data Release and NDA
Aldeyra Therapeutics plans to resubmit the New Drug Application (NDA) for reproxalap aimed at treating dry eye disease after receiving constructive feedback from the FDA. The FDA's previous Complete Response Letter indicated that additional studies are needed to demonstrate efficacy. In response, Aldeyra's recent dry eye chamber trial showed statistical significance in favor of reproxalap, which the company believes addresses the FDA's concerns. Continuous discussions with the FDA will determine the pathway for the NDA resubmission.
Read more →ALDX▲ +9%on this news· ran to +20% by day 3shared move
Aldeyra Therapeutics Appoints Chip Clark to Board
Aldeyra Therapeutics has appointed Chip Clark to its Board of Directors, enhancing its leadership team with his extensive experience in the biopharmaceutical sector. Currently the CEO of Vibrant Biomedicines, Clark's background includes key roles at Genocea Biosciences and Vanda Pharmaceuticals. His expertise is expected to support Aldeyra's mission to advance innovative therapies addressing significant medical needs. Aldeyra's diversified pipeline targets immune-mediated and metabolic diseases, with key product candidates in late-stage development.
Read more →ALDX▼ -73.3%on this news
C O N F E R E N C E C A L L Reproxalap for the Potential Treatment of Dry Eye Disease: Regulatory Update
Aldeyra Therapeutics received a Complete Response Letter from the FDA regarding its New Drug Application for reproxalap, citing insufficient evidence of efficacy in treating dry eye symptoms. The letter indicates that further studies are needed to provide the necessary data for resubmission. With ongoing trials expected to yield results soon, Aldeyra is positioned to pursue potential resubmission, backed by a strong cash position. The regulatory landscape remains flexible, with timelines subject to change based on FDA workload and other factors.
Read more →About Aldeyra Therapeutics, Inc.
Headquarters131 HARTWELL AVENUE, LEXINGTON, MA, 02421
Founded2004
BIOPHARMAWATCH ELITE PLUS
Trade the next ALDX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime